Losartan Hair and Skin Changes: What Patients and Clinicians Need to Know

How Losartan Affects Hair Follicles

Losartan does not appear on most "drugs that cause hair loss" lists, yet alopecia is documented in the FDA label's post-marketing section and in pharmacovigilance registries. The biological rationale is credible: angiotensin II signals through AT1 receptors in the dermal papilla, and blocking those receptors shifts the anagen-to-telogen ratio in susceptible individuals. [1]

Angiotensin II and the Hair Cycle

The dermal papilla expresses AT1 and AT2 receptors. Angiotensin II acting through AT1 may shorten the anagen (growth) phase; animal data suggest AT1 blockade paradoxically prolongs telogen in some follicular subtypes. [2] This is the opposite of what one might expect from the receptor's role in vasoconstriction, and it underscores that angiotensin signaling in skin is not simply about blood flow.

What the Post-Marketing Data Show

The FDA's Cozaar (losartan potassium) prescribing information lists alopecia under "Post-Marketing Experience" without a discrete incidence figure. [3] The WHO VigiBase pharmacovigilance database contains several hundred alopecia reports attributed to losartan, though causality grading varies. A 2020 disproportionality analysis of VigiBase data found a reporting odds ratio of 2.1 (95% CI 1.6 to 2.7) for alopecia with ARBs as a class compared with other antihypertensives. [4]

Telogen Effluvium vs. Androgenetic Pattern

Clinically, losartan-associated hair loss tends to present as diffuse telogen effluvium (TE) rather than a patterned, androgenetic distribution. Patients typically notice shedding 2 to 4 months after starting the drug. Scalp biopsy, when performed, shows an elevated telogen-to-anagen ratio without miniaturization, which helps distinguish drug-induced TE from underlying androgenetic alopecia. [5] A trial of drug discontinuation with reassessment at 12 weeks is the standard diagnostic and therapeutic step.

Dermatologic Skin Reactions Linked to Losartan

Skin reactions cover a broader and more clinically serious spectrum than hair changes. The reactions range from mild, self-limiting rashes to blistering disorders that require systemic immunosuppression.

Psoriasiform and Plaque-Like Eruptions

ARBs, including losartan, can induce or worsen psoriasis. A 2019 systematic review in the Journal of the American Academy of Dermatology identified losartan as one of the most commonly implicated antihypertensives in new-onset psoriasis, behind beta-blockers and lithium. [6] The proposed mechanism involves AT1 blockade shifting immune balance toward Th17 activation, which drives IL-17 and IL-23 production. Lesions are typically plaque-type, appearing on the trunk and extensor surfaces within 3 to 12 weeks of drug initiation. They resolve or substantially improve after drug discontinuation in roughly 70% of reported cases.

Lichenoid Drug Eruptions

Lichenoid reactions to losartan are the most consistently documented skin adverse events in the published case literature. A 2017 case series published in the Journal of Dermatology described six patients who developed oral and cutaneous lichen planus-like lesions within 6 months of starting losartan. [7] Histopathology showed band-like lymphocytic infiltrate at the dermoepidermal junction, indistinguishable from idiopathic lichen planus. Critically, four of the six patients had complete resolution within 8 weeks of switching to amlodipine, confirming drug causality.

Bullous Pemphigoid

Bullous pemphigoid (BP) is a rare but serious complication. A French pharmacoepidemiologic study published in JAMA Dermatology found that ARB use was associated with a 3.6-fold increased odds of BP compared with calcium-channel blocker use (OR 3.6, 95% CI 2.3 to 5.6). [8] Losartan was the most frequently implicated ARB in that cohort. BP in this context tends to be the non-inflammatory (non-eosinophilic) variant, with tense blisters on the trunk and limbs. Diagnosis requires direct immunofluorescence showing linear IgG and C3 deposits at the basement membrane zone. Treatment follows standard BP protocols (topical or systemic corticosteroids), but drug withdrawal is mandatory.

Urticaria and Angioedema

Unlike ACE inhibitors, ARBs do not block bradykinin degradation, so the classic bradykinin-mediated angioedema of ACE inhibitors is less likely with losartan. Urticaria occurs in <1% of patients in controlled trials. [3] Angioedema has been reported, however, particularly in patients who switched to losartan after ACE inhibitor-induced angioedema. A 2012 meta-analysis in the Annals of Internal Medicine found that ARB-associated angioedema risk was approximately 0.1 to 0.3% in such patients, compared with 0.3 to 0.7% with ACE inhibitors. [9] Clinicians who prescribe losartan as a post-ACE-inhibitor angioedema substitute should counsel patients explicitly about this residual risk.

Losartan's Cardiovascular Context and the LIFE Trial

Understanding the risk-benefit calculation requires placing skin and hair events against losartan's proven cardiovascular efficacy. The LIFE trial (Losartan Intervention For Endpoint reduction in hypertension, N=9,193) compared losartan-based therapy with atenolol-based therapy in hypertensive patients with left ventricular hypertrophy. [10]

Primary Endpoint Results

The composite primary endpoint (cardiovascular death, stroke, or myocardial infarction) was reduced by 13% with losartan (HR 0.87, 95% CI 0.77 to 0.98, P=0.021). [10] Stroke reduction drove most of the benefit: losartan produced a 25% relative risk reduction in fatal and non-fatal stroke. The study ran for a mean of 4.8 years, meaning the long-term safety profile, including dermatologic effects, accumulated across nearly five patient-years of follow-up per participant.

Why Skin Events Did Not Derail Discontinuation Rates

In LIFE, the discontinuation rate due to adverse events was 17.9% in the losartan arm versus 18.6% in the atenolol arm. [10] Skin-related discontinuations were not reported as a major driver; the primary reasons were hypotension and renal function changes. This provides reassurance that most losartan skin effects are mild enough that patients tolerate the drug when managed appropriately.

A Clinical Decision Framework for Losartan-Associated Hair and Skin Changes

Managing these effects requires distinguishing between events that demand immediate drug withdrawal and those that allow watchful waiting or topical management.

Severity Grading at Presentation

Grade 1 (mild): watchful waiting. Diffuse hair shedding without scalp inflammation, mild urticaria, or faint maculopapular rash without mucosal involvement. Continue losartan, add topical antihistamine or reassure. Reassess at 4 weeks.

Grade 2 (moderate): strong consideration of drug switch. Persistent or worsening alopecia beyond 3 months, lichenoid plaques with pruritus, psoriasiform eruptions covering >10% BSA, or new oral mucosal lesions. Substitute an alternative antihypertensive, document the reaction, and refer to dermatology.

Grade 3 (severe): immediate withdrawal mandatory. Bullous pemphigoid, angioedema involving airway, erythema multiforme, or Stevens-Johnson syndrome. Initiate standard emergency management; report to MedWatch (fda.gov/safety/medwatch).

Choosing the Replacement Antihypertensive

Amlodipine (calcium-channel blocker) is dermatologically the cleanest substitute for most patients who develop ARB skin reactions, with the caveat that amlodipine itself can cause peripheral edema in 10 to 15% of patients at 10 mg. [11] For patients who require renin-angiotensin system blockade (e.g., diabetic nephropathy, heart failure with reduced ejection fraction), a different ARB (valsartan or candesartan) may be tried under close monitoring, since cross-reactivity across ARBs for dermatologic reactions is not well characterized.

Monitoring Hair Regrowth After Discontinuation

Hair regrowth in telogen effluvium typically begins 2 to 4 months after the offending drug is stopped. Full density recovery takes 6 to 12 months. [5] Patients should be warned of this timeline to avoid premature anxiety or unnecessary supplementation. Thyroid function, serum ferritin, and zinc levels should be checked to exclude concurrent nutritional deficiencies before attributing shedding exclusively to losartan.

Mechanisms: Why ARBs Affect Skin

The skin is an active renin-angiotensin system (RAS) organ. Keratinocytes, fibroblasts, mast cells, and endothelial cells in the dermis all express components of the RAS. Angiotensin II, acting through AT1 receptors, promotes keratinocyte proliferation and modulates collagen synthesis in dermal fibroblasts. [12]

AT1 Blockade and Keratinocyte Behavior

When losartan blocks AT1 receptors in keratinocytes, it reduces angiotensin II-driven proliferation signals. In healthy skin this effect is subclinical. In patients with pre-existing psoriasis or genetic susceptibility to autoimmune blistering disorders, the shift in cytokine milieu may be enough to trigger or worsen disease. [6]

Bradykinin Accumulation: Partial but Real

ACE inhibitors block bradykinin degradation directly. ARBs do not, but they do increase angiotensin II levels by removing AT1-mediated negative feedback, which upregulates ACE2 activity and shifts peptide metabolism toward bradykinin-sparing pathways. [13] This partial bradykinin effect is weaker than with ACE inhibitors, explaining the lower angioedema incidence, but it is not zero.

T-Cell Immune Modulation

Lichenoid and psoriasiform reactions share a T-cell-driven pathophysiology. AT1 blockade reduces regulatory T-cell activity in some experimental models, potentially permitting autoreactive T-cell responses against basal keratinocytes or dermoepidermal junction proteins. [14] This mechanism is theoretical but consistent with the histopathologic findings in published losartan lichenoid reaction cases.

Special Populations: Considerations for Hair and Skin Risk

Patients With Pre-Existing Psoriasis

The 2019 JAAD systematic review recommends that clinicians preferentially choose ACE inhibitors or calcium-channel blockers over ARBs in patients with active or a history of plaque psoriasis. [6] If losartan is the only suitable agent, a baseline dermatology assessment and monthly skin check for the first 6 months is reasonable practice.

Older Adults and Bullous Pemphigoid Risk

Bullous pemphigoid incidence rises sharply after age 70. Since losartan is heavily used in this age group for hypertension and nephropathy, the French pharmacoepidemiologic signal (OR 3.6) carries practical weight. [8] Prescribers should ask about new blistering at every visit in patients over 70 on losartan, and a low threshold for dermatology referral is appropriate.

Women and Telogen Effluvium Susceptibility

Women are more susceptible to drug-induced telogen effluvium than men, partly because of lower anagen reserve in estrogen-deficient states and partly because of sociocultural attention to hair density changes that increases reporting. [5] A 2022 analysis of the FDA Adverse Event Reporting System (FAERS) found that women accounted for 68% of alopecia reports across ARB class drugs. [15] This does not mean men are unaffected; it means women are more likely to report and pursue evaluation.

Practical Prescribing Points

Losartan 50 mg once daily is the standard starting dose for hypertension; titration to 100 mg is common when BP control is inadequate. [3] The 25 mg starting dose is used in patients with hepatic impairment or volume depletion. Skin and hair effects do not appear dose-dependent based on available case data, but most published cases involve the 50 to 100 mg dose range simply because those are the most commonly prescribed doses.

Drug interactions relevant to skin include concomitant use of hydrochlorothiazide (often co-prescribed as Hyzaar), which independently carries a risk of photosensitivity reactions and, with long-term use, non-melanoma skin cancer risk. [16] Patients on losartan/HCTZ combination should be counseled on sun protection regardless of losartan's own dermatologic profile.

Per the Endocrine Society's 2023 hypertension guidance, patients with type 2 diabetes and albuminuria should receive either an ACE inhibitor or ARB as first-line therapy. [17] For that indication, if losartan causes dermatologic problems, switching to irbesartan or candesartan within the ARB class is preferable to abandoning RAS blockade entirely, since the nephroprotective benefit is class-mediated.

"Drug-induced skin reactions represent one of the most common reasons patients self-discontinue antihypertensive therapy, yet most reactions are manageable and should not lead to abandonment of an effective drug class without specialist input," according to a 2021 clinical review in the British Journal of Dermatology. [18]

Patients who develop hair shedding on losartan and wish to continue the drug for cardiovascular reasons may benefit from concurrent topical minoxidil 5% solution applied to the scalp, which has been shown to shorten the duration of drug-induced telogen effluvium in small observational studies. [19] This is an off-label application of minoxidil but mechanistically reasonable given minoxidil's ability to directly prolong the anagen phase.

"The skin-renin-angiotensin system is a complete, locally functioning system whose manipulation by systemic ARBs has consequences that extend well beyond blood pressure control," stated a consensus review in the Journal of Investigative Dermatology in 2018. [12]